Greater transparency on clinical trial results would help reduce off-label promotion—the promotion of medicines for uses for which they have not been approved. Looking at the US since 2004, I […]
Open data
Jim Murray: Will governments support transparency for clinical trials?
Criticism of EU law is often aimed at an amorphous “Brussels,” but in many cases member states are the problem—as with the proposal to revise the Clinical Trials Directive. The […]
Jim Murray: The EU, transparency, and access to clinical trial results
How is the EU involved in transparency and access to clinical trial results? Many readers will know this already, but perhaps not all. For obvious reasons, health professionals have tended […]